Curaleaf (OTCMKTS:CURLF – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.17, Zacks reports. Curaleaf had a negative return on equity of 8.06% and a negative net margin of 7.76%.The firm had revenue of $324.23 million during the quarter, compared to analyst estimates of $316.62 million.
Curaleaf Stock Up 1.2%
OTCMKTS:CURLF traded up $0.05 during trading hours on Thursday, reaching $3.86. 476,155 shares of the company traded hands, compared to its average volume of 1,029,656. The company has a current ratio of 1.52, a quick ratio of 0.76 and a debt-to-equity ratio of 1.14. The business’s 50-day moving average price is $2.55 and its two-hundred day moving average price is $2.59. Curaleaf has a 1 year low of $0.72 and a 1 year high of $5.05. The stock has a market capitalization of $2.65 billion, a P/E ratio of -29.66 and a beta of 1.58.
Analyst Upgrades and Downgrades
Separately, Zacks Research upgraded Curaleaf from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Three analysts have rated the stock with a Strong Buy rating and one has given a Buy rating to the company’s stock. Based on data from MarketBeat.com, Curaleaf presently has a consensus rating of “Strong Buy”.
About Curaleaf
Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.
Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.
Featured Stories
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
